These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 15726382)
21. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. Parton M; Gore M; Eisen T J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544 [TBL] [Abstract][Full Text] [Related]
30. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Merseburger AS; Simon A; Waalkes S; Kuczyk MA Expert Rev Anticancer Ther; 2009 Oct; 9(10):1429-34. PubMed ID: 19828003 [TBL] [Abstract][Full Text] [Related]
31. New perspectives in the treatment of metastatic renal cell carcinoma. Barrière J; Hoch B; Ferrero JM Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727 [TBL] [Abstract][Full Text] [Related]
32. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204 [TBL] [Abstract][Full Text] [Related]
33. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma. Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299 [TBL] [Abstract][Full Text] [Related]
34. Chemotherapy of metastatic renal cancer. Denis L; Van Oosterom A Semin Surg Oncol; 1988; 4(2):91-4. PubMed ID: 3293156 [TBL] [Abstract][Full Text] [Related]
35. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma. Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040 [TBL] [Abstract][Full Text] [Related]
36. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study. Padrik P; Leppik K; Arak A Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918 [TBL] [Abstract][Full Text] [Related]
38. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Donskov F Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677 [TBL] [Abstract][Full Text] [Related]
39. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). Passalacqua R; Caminiti C; Buti S; Porta C; Camisa R; Braglia L; Tomasello G; Vaglio A; Labianca R; Rondini E; Sabbatini R; Nastasi G; Artioli F; Prati A; Potenzoni M; Pezzuolo D; Oliva E; Alberici F; Buzio C; J Immunother; 2014; 37(9):440-7. PubMed ID: 25304727 [TBL] [Abstract][Full Text] [Related]
40. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S; BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]